News Focus
News Focus
Followers 64
Posts 7751
Boards Moderated 1
Alias Born 01/02/2003

Re: Number sleven post# 439768

Tuesday, 10/21/2025 4:26:14 PM

Tuesday, October 21, 2025 4:26:14 PM

Post# of 447440
N.sleven....Even if Amarin prevails in their case against Hikma, Hikma will then institute lengthy appeals.
It is true,however, that Amarin's winning the case against Hikma may make other generic cos. think twice against infringing on Amarin's CVD patent.

Amarin's main opportunity for the near term revolves around the approval of Lr-ET-EPA by the patent office and then by the FDA.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News